- Home
- PROK vs MBI Comparison
PROK vs MBI Comparison
Compare PROK & MBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- MBI
- Stock Information
- Founded
- PROK 2015
- MBI 1973
- Country
- PROK United States
- MBI United States
- Employees
- PROK N/A
- MBI N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- MBI Property-Casualty Insurers
- Sector
- PROK Health Care
- MBI Finance
- Exchange
- PROK Nasdaq
- MBI Nasdaq
- Market Cap
- PROK 334.8M
- MBI 377.2M
- IPO Year
- PROK N/A
- MBI 1987
- Fundamental
- Price
- PROK $3.11
- MBI $7.06
- Analyst Decision
- PROK Buy
- MBI Buy
- Analyst Count
- PROK 5
- MBI 1
- Target Price
- PROK $6.25
- MBI $8.00
- AVG Volume (30 Days)
- PROK 2.5M
- MBI 353.0K
- Earning Date
- PROK 11-11-2025
- MBI 11-06-2025
- Dividend Yield
- PROK N/A
- MBI N/A
- EPS Growth
- PROK N/A
- MBI N/A
- EPS
- PROK N/A
- MBI N/A
- Revenue
- PROK $527,000.00
- MBI $108,000,000.00
- Revenue This Year
- PROK $338.06
- MBI N/A
- Revenue Next Year
- PROK N/A
- MBI N/A
- P/E Ratio
- PROK N/A
- MBI N/A
- Revenue Growth
- PROK N/A
- MBI 285.71
- 52 Week Low
- PROK $0.46
- MBI $3.28
- 52 Week High
- PROK $7.13
- MBI $8.26
- Technical
- Relative Strength Index (RSI)
- PROK 54.93
- MBI 42.49
- Support Level
- PROK $2.34
- MBI $7.02
- Resistance Level
- PROK $3.02
- MBI $7.55
- Average True Range (ATR)
- PROK 0.17
- MBI 0.31
- MACD
- PROK 0.03
- MBI -0.10
- Stochastic Oscillator
- PROK 65.59
- MBI 0.00
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About MBI MBIA Inc.
MBIA Inc provides financial guaranty insurance for municipal bonds and asset-backed securities in the United States and internationally. It offers an unconditional guarantee to repay the principal and interest on these securities if the issuer defaults. MBIA insures bonds sold in the primary and secondary markets, as well as those held in unit investment trusts and mutual funds. It operates in three segments: the United States Public Finance Insurance, which derives maximum revenue, Corporate, and International & Structured Finance Insurance. U.S. public finance insurance portfolio is managed through the National Public Finance Guarantee Corporation. International & structured finance insurance business is managed through MBIA Insurance Corporation and its subsidiary.